just reading through the announcement... Initial highlights are...
Stirling Products is currently in advanced negotiation for: • acquisition of a $30 million near new, fully licensed pharmaceutical production facility on extra-ordinary terms • over $5 million in government grants …. and positioned for: • significant sales revenues – commencing next 3 – 6 months • targeted cash flow breakeven by mid 2010 • targeted annualised sales revenue of min $30M by end 2010
The market for herbal and botanical products is forecast to grow by over 168% over the next 5 years to over US$33 billion • Over 60% of all New Chemical Entities for prescription pharmaceuticals in the last 5 years have been derived from natural or synthesized natural sources
ImmunoXel has demonstrated in all its clinical trials that it: • is a powerful immunomodulator and adjuvant • substantively tunes the Immune System • enhances efficacy of - antibiotics, viral therapies and chemotherapies • can substantially shorten drug and chemotherapy treatment duration • can reduce and reverse treatment toxicity side-effects – esp. in liver and kidneys • is market ready for treatment of TB, TB/HIV, AIDS • over 800 patients treated in clinical trials – mainly TB, TB/HIV but also AIDS and influenza
• Enhances efficacy of drugs 2-10 fold • Shortens therapy duration 3-12 fold • Reduces and reverses toxicity of current TB drugs
World Health Organisation estimates (2007) over 1 million people in each of India and China have TB ( page 15)
Estimated Number of People Living with HIV/AIDS,(2007) over 30 million ( page 17)
There are plenty more pages of info in the presentation that I expect will spark some interest in India
STI Price at posting:
1.0¢ Sentiment: ST Buy Disclosure: Held